GRACEcast Lung Cancer Audio

cancerGRACE - H. Jack West, MD

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

300 Episoden

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?
31.7.2014
4:36
Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
Management of Rare Kidney Tumors
29.7.2014
1:55
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.
Verpasse keine Episode von “GRACEcast Lung Cancer Audio” und abonniere ihn in der kostenlosen GetPodcast App.
Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?
27.7.2014
5:28
The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Treatment for Kidney Cancer
24.7.2014
2:03
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?
22.7.2014
2:27
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
How is the Heng Criteria Applied to Kidney Cancer Patients?
20.7.2014
4:40
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
17.7.2014
7:28
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
What is PD1 and PDL1 in Kidney Cancer?
15.7.2014
3:15
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
Zykadia for ALK Positive Lung Cancer: New Drug, New Hope
13.7.2014
7:22
The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
No Clear Answer for Non-Clear Cell Kidney Cancer
10.7.2014
5:41
Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.

Weitere Episoden

Hol dir die ganze Welt der Podcasts mit der kostenlosen GetPodcast App.

Abonniere alle deine Lieblingspodcasts, höre Episoden auch offline und erhalte passende Empfehlungen für Podcasts, die dich wirklich interessieren.

Ein Unternehmen von

GRACEcast Lung Cancer Audio

cancerGRACE - H. Jack West, MD

300 Episoden

Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy?

Management of Rare Kidney Tumors

Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation?

NanoString Treatment for Kidney Cancer

Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer?

How is the Heng Criteria Applied to Kidney Cancer Patients?

Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?

What is PD1 and PDL1 in Kidney Cancer?

Zykadia for ALK Positive Lung Cancer: New Drug, New Hope

No Clear Answer for Non-Clear Cell Kidney Cancer